# Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD

> **NCT04580420** · PHASE2 · RECRUITING · sponsor: **Dicerna Pharmaceuticals, Inc., a Novo Nordisk company** · enrollment: 28 (estimated)

## Conditions studied

- Primary Hyperoxaluria Type 1
- End Stage Renal Disease

## Interventions

- **DRUG:** DCR-PHXC

## Key facts

- **NCT ID:** NCT04580420
- **Lead sponsor:** Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-04-15
- **Primary completion:** 2031-12-30
- **Final completion:** 2032-01-30
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2025-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04580420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04580420, "Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04580420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*